Fagron NV (FAGR) - Total Liabilities
Based on the latest financial reports, Fagron NV (FAGR) has total liabilities worth €686.87 Million EUR (≈ $803.03 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fagron NV - Total Liabilities Trend (2004–2025)
This chart illustrates how Fagron NV's total liabilities have evolved over time, based on quarterly financial data. See FAGR working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Fagron NV Competitors by Total Liabilities
The table below lists competitors of Fagron NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sigma Lithium Resources Corp
V:SGML
|
Canada | CA$237.12 Million |
|
Greatoo Inc
SHE:002031
|
China | CN¥1.92 Billion |
|
UFP Technologies Inc
NASDAQ:UFPT
|
USA | $248.91 Million |
|
Attendo AB (publ)
ST:ATT
|
Sweden | Skr18.93 Billion |
|
Cimpress plc
F:3UF
|
Germany | €2.51 Billion |
|
CBIZ Inc
NYSE:CBZ
|
USA | $2.74 Billion |
|
Zhejiang DiAn Diagnostics Co
SHE:300244
|
China | CN¥5.41 Billion |
|
Pehuenche
SN:PEHUENCHE
|
Chile | CL$49.99 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Fagron NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FAGR market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fagron NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fagron NV (2004–2025)
The table below shows the annual total liabilities of Fagron NV from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €686.87 Million ≈ $803.03 Million |
+18.80% |
| 2024-12-31 | €578.16 Million ≈ $675.93 Million |
+7.20% |
| 2023-12-31 | €539.33 Million ≈ $630.53 Million |
-4.10% |
| 2022-12-31 | €562.38 Million ≈ $657.48 Million |
+18.41% |
| 2021-12-31 | €474.95 Million ≈ $555.27 Million |
-4.05% |
| 2020-12-31 | €495.01 Million ≈ $578.72 Million |
-10.78% |
| 2019-12-31 | €554.80 Million ≈ $648.62 Million |
+17.28% |
| 2018-12-31 | €473.06 Million ≈ $553.05 Million |
+15.61% |
| 2017-12-31 | €409.17 Million ≈ $478.36 Million |
-42.79% |
| 2016-12-31 | €715.18 Million ≈ $836.12 Million |
-5.17% |
| 2015-12-31 | €754.15 Million ≈ $881.69 Million |
-7.67% |
| 2014-12-31 | €816.81 Million ≈ $954.94 Million |
+25.75% |
| 2013-12-31 | €649.53 Million ≈ $759.36 Million |
+29.00% |
| 2012-12-31 | €503.51 Million ≈ $588.66 Million |
+9.51% |
| 2011-12-31 | €459.78 Million ≈ $537.53 Million |
+25.81% |
| 2010-12-31 | €365.47 Million ≈ $427.27 Million |
+32.51% |
| 2009-12-31 | €275.81 Million ≈ $322.45 Million |
+18.78% |
| 2008-12-31 | €232.20 Million ≈ $271.47 Million |
+37.20% |
| 2007-12-31 | €169.24 Million ≈ $197.86 Million |
-11.19% |
| 2006-12-31 | €190.58 Million ≈ $222.80 Million |
+0.74% |
| 2005-12-31 | €189.17 Million ≈ $221.16 Million |
+10.85% |
| 2004-12-31 | €170.65 Million ≈ $199.51 Million |
-- |
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Com… Read more